Viewing Study NCT03430895

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:02 PM
Ignite Modification Date: 2025-12-30 @ 11:17 PM
Study NCT ID: NCT03430895
Status: COMPLETED
Last Update Posted: 2021-12-01
First Post: 2018-02-07
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Transitional Cell Carcinoma of the Urothelial Tract View
None Small Cell of the Bladder View
None Adenocarcinoma of the Bladder View
None Squamous Cell Carcinoma of the Bladder View
None Metastatic Bladder Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Tremelimumab View
None immunotherapy View
None 17-511 View
None Durvalumab (MEDI4736) View